Zobrazeno 1 - 10 of 2 519 pro vyhledávání: '"Pecquet, C."'
1
Akademický článek
Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease.
Autor: Felten R; Service de Rhumatologie - Centre National de Référence des maladies auto-immuneset et auto-inflammatoires systémiques rares RESO, Hopitaux universitaires de Strasbourg, Strasbourg, France.; Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR 3572, IBMC, Strasbourg, France., Foray AP; Université Paris Cité, CNRS UMR 8253, INSERM UMR 1151, Institut Necker Enfants Malades-INEM, Paris, France., Schneider P; Department of Immunobiology, University of Lausanne, Lausanne, Switzerland., Marquet C; Université Paris Cité, CNRS UMR 8253, INSERM UMR 1151, Institut Necker Enfants Malades-INEM, Paris, France., Pecquet C; Université Paris Cité, CNRS UMR 8253, INSERM UMR 1151, Institut Necker Enfants Malades-INEM, Paris, France., Monneaux F; Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR 3572, IBMC, Strasbourg, France., Dumortier H; Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR 3572, IBMC, Strasbourg, France., Sibilia J; Service de Rhumatologie - Centre National de Référence des maladies auto-immuneset et auto-inflammatoires systémiques rares RESO, Hopitaux universitaires de Strasbourg, Strasbourg, France., Valette F; Université Paris Cité, CNRS UMR 8253, INSERM UMR 1151, Institut Necker Enfants Malades-INEM, Paris, France., Chatenoud L; Université Paris Cité, CNRS UMR 8253, INSERM UMR 1151, Institut Necker Enfants Malades-INEM, Paris, France., Gottenberg JE; Service de Rhumatologie - Centre National de Référence des maladies auto-immuneset et auto-inflammatoires systémiques rares RESO, Hopitaux universitaires de Strasbourg, Strasbourg, France jacques-eric.gottenberg@chru-strasbourg.fr.; Immunologie, Immunopathologie et Chimie Thérapeutique, CNRS UPR 3572, IBMC, Strasbourg, France.
Publikováno v: RMD open [RMD Open] 2024 Aug 28; Vol. 10 (3). Date of Electronic Publication: 2024 Aug 28.
Zobrazit plný text záznamu
2
Akademický článek
Traitement de l’urticaire chronique par omalizumab : données en vie réelle
Autor: Hamelin, A., Amsler, E., Mathelier-Fusade, P., Pecquet, C., Bayrou, O., Barbaud, A., Soria, A.
Publikováno v: In Annales de Dermatologie et de Vénéréologie January 2019 146(1):9-18
Zobrazit plný text záznamu
3
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
Autor: Lecomte, S, Devreux, J, de Streel, G, van Baren, N, Havelange, V, Schröder, D, Vaherto, N, Vanhaver, C, Vanderaa, C, Dupuis, N, Pecquet, C, Coulie, PG, Constantinescu, SN, Lucas, S
Publikováno v: Blood, Vol. 141, no.5, p. 490-502 (2023)
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine production leading to bone marrow (BM) fibrosis and insufficiency. Current tre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::834d3a848c0dd3902fc307e66f24f9a9
https://doi.org/10.1182/blood.2022017097
Zobrazit plný text záznamu
4
Akademický článek
Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study.
Autor: Sola-Gazagnes A; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France. agnes.sola@aphp.fr., Pecquet C; Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Service d'Allergologie Dermatologie, Paris, France., Berré S; Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France., Achenbach P; Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Diabetes Research, Munich-Neuherberg, Germany.; Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Forschergruppe Diabetes, Munich, Germany., Pierson LA; Assistance Publique-Hôpitaux de Paris, Hôtel-Dieu, Service de Pharmacie, Pharmacologie, Toxicologie, Paris, France., Virmoux-Buisson I; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France., M'Bemba J; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France., Elgrably F; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France., Moguelet P; Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Service d'Anatomo-Pathologie, Sorbonne Université, Faculté de Médecine, Paris, France., Boitard C; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France.; Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France., Caillat-Zucman S; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Laboratoire d'Immunologie, Paris, France.; Université Paris Cité, Inserm UMR976, Institut de Recherche Saint-Louis, Paris, France., Laanani M; Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Biostatistics and Epidemiology Unit, Paris, France., Coste J; Université Paris Cité, Assistance Publique-Hôpitaux de Paris, Cochin Hospital, Biostatistics and Epidemiology Unit, Paris, France., Larger E; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France.; Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France., Mallone R; Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires de Paris Centre-Université Paris Cité, Cochin Hospital, Service de Diabétologie et Immunologie Clinique, Paris, France.; Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France.
Publikováno v: Diabetologia [Diabetologia] 2022 Aug; Vol. 65 (8), pp. 1278-1290. Date of Electronic Publication: 2022 May 04.
Zobrazit plný text záznamu
5
Akademický článek
Étude de 19 cas d’allergie aux héparines prouvée par des tests cutanés
Autor: Phan, C., Vial-Dupuy, A., Autegarden, J.-E., Amsler, E., Gaouar, H., Abuaf, N., Pecquet, C., Francès, C., Soria, A.
Publikováno v: In Annales de dermatologie et de venereologie January 2014 141(1):23-29
Zobrazit plný text záznamu
6
Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms
Autor: Pecquet, C, Papadopoulos, N, Balligand, T, Chachoua, I, Tisserand, A, Vertenoeil, G, Nédélec, A, Vertommen, D, Roy, A, Marty, C, Nivarthi, H, Defour, J-P, El-Khoury, M, Hug, E, Majoros, A, Xu, E, Zagrijtschuk, O, Fertig, TE, Marta, DS, Gisslinger, H, Gisslinger, B, Schalling, M, Casetti, I, Rumi, E, Pietra, D, Cavalloni, C, Arcaini, L, Cazzola, M, Komatsu, N, Kihara, Y, Sunami, Y, Edahiro, Y, Araki, M, Lesyk, R, Buxhofer-Ausch, V, Heibl, S, Pasquier, F, Havelange, V, Plo, I, Vainchenker, W, Kralovics, R, Constantinescu, SN
Publikováno v: Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms, Vol. 141, no. 8, p. 917-929 (2023)
Mutant calreticulin (CALR) proteins resulting from a −1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2e9b8c21dd22fb6d72ded0ad3f2c03b
https://pubmed.ncbi.nlm.nih.gov/36356299
Zobrazit plný text záznamu
7
Akademický článek
Allergie de contact aux accessoires de sport
Autor: Castelain, M., Pecquet, C.
Publikováno v: In Revue Francaise d'Allergologie 2009 49(3):254-258
Zobrazit plný text záznamu
8
Akademický článek
Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
Autor: Defour JP; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Leroy E; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Dass S; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, Newyork, United States., Balligand T; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Levy G; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Brett IC; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, Newyork, United States., Papadopoulos N; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Mouton C; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Genet L; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Pecquet C; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Staerk J; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium., Smith SO; Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, Newyork, United States., Constantinescu SN; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WEL Research Institute, WELBIO Department, Wavre, Belgium.; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
Publikováno v: ELife [Elife] 2023 Jun 20; Vol. 12. Date of Electronic Publication: 2023 Jun 20.
Zobrazit plný text záznamu
10
Akademický článek
Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.
Autor: Balligand T; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium., Achouri Y; de Duve Institute, LPAD Unit, Université catholique de Louvain, Brussels, Belgium., Pecquet C; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium., Gaudray G; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium., Colau D; Ludwig Institute for Cancer Research, Brussels, Belgium., Hug E; MyeloPro Research and Diagnostics GmbH, Vienna, Austria., Rahmani Y; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium., Stroobant V; Ludwig Institute for Cancer Research, Brussels, Belgium., Plo I; INSERM, Unité Mixte de Recherche 1170, Gustave Roussy, Villejuif, France.; Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.; Gustave Roussy, Mixte de Recherche 1170, Villejuif, France., Vainchenker W; INSERM, Unité Mixte de Recherche 1170, Gustave Roussy, Villejuif, France.; Paris-Saclay, Unité Mixte de Recherche 1170, Institut Gustave Roussy, Villejuif, France.; Gustave Roussy, Mixte de Recherche 1170, Villejuif, France., Kralovics R; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Van den Eynde BJ; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium., Defour JP; Ludwig Institute for Cancer Research, Brussels, Belgium.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium.; Cliniques Universitaires de Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Constantinescu SN; Ludwig Institute for Cancer Research, Brussels, Belgium. Stefan.Constantinescu@bru.licr.org.; de Duve Institute, Université catholique de Louvain, Brussels, Belgium. Stefan.Constantinescu@bru.licr.org.; WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium. Stefan.Constantinescu@bru.licr.org.; Cliniques Universitaires de Saint-Luc, Université catholique de Louvain, Brussels, Belgium. Stefan.Constantinescu@bru.licr.org.
Publikováno v: Leukemia [Leukemia] 2020 Feb; Vol. 34 (2), pp. 510-521. Date of Electronic Publication: 2019 Aug 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje